Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply
Resilience and Lilly expand strategic partnership first established in 2023 Investment will significantly increase U.S. production of Lilly’s...
Resilience and Lilly expand strategic partnership first established in 2023 Investment will significantly increase U.S. production of Lilly’s...
BLUE ASH, Ohio, June 18, 2026 – Resilience, along with Ohio Governor Mike DeWine, JobsOhio, the City of Blue Ash, and REDI Cincinnati, today...
Biomanufacturing safety and efficacy depend on well-controlled, compliant manufacturing processes. Can a virtual model truly give biomanufacturing...
Are you an innovator company looking for a reliable and innovative partner? You have come to the right place.
Resilience and Pluristyx have entered a strategic collaboration to accelerate and simplify the transition of promising iPSC-derived therapies from...
The proliferation of recombinant protein therapies has driven the need for new capacity in the biotherapeutic manufacturing space. Monoclonal...
How Early-Phase Companies Can Future-Proof Their Cell Therapies The following was extracted from a conversation with Eytan Abraham “Q: How should...
RESILIENCE